Alliance Global Partners lowered the firm’s price target on Genprex to $7.50 from $8 and keeps a Buy rating on the shares post the Q2 report. The firm remains positive on the prospects for Genprex’s development pipeline in the second half of 2024, and notes a number of milestones have been hit to date this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX: